{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Safety was assessed by monitoring adverse events and serious adverse events; the association with study treatment was assessed, and severity graded using Common Terminology Criteria for Adverse Events (CTCAE) v.4.03. Number of events that were Possible, Probable or Definitely related to study treatment.","groups":[{"description":"Transarterial Chemoperfusion treatment with cisplatin (35 mg/m\\^2), methotrexate (100 mg/m\\^2) and gemcitabine (1000 mg/m\\^2).\n\nPatients undergo angiogram and transarterial chemoperfusion treatment in every 4 weeks (3-6 weeks interval allowed) when cisplatin, methotrexate and gemcitabine will be administered into the thoracic aorta and/or the internal mammary artery on the side of the disease.\n\nQuality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.\n\nCisplatin: The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m\\^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.\n\nMethotrexate: The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m\\^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m\\^2).\n\nGemcitabine: The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m\\^2 BSA. During the lead in phase of the study, 3 patients will be treated with regular doses of gemcitabine.\n\nLung Cancer Symptom Scale for Mesothelioma Questionnaire: Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.","id":"OG000","title":"Chemoperfusion + Questionnaire"}],"paramType":"NUMBER","populationDescription":"All evaluable participants. Study patients cannot be analyzed separately. No dose limiting toxicities observed, therefore all participants received same dosing.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Occurrence of Treatment Related Toxicity","type":"SECONDARY","unitOfMeasure":"related adverse events"}